Media headlines about Sunesis Pharmaceuticals (NASDAQ:SNSS) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sunesis Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.693591483249 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
SNSS has been the topic of several research reports. Oppenheimer initiated coverage on Sunesis Pharmaceuticals in a report on Thursday, December 14th. They set a “buy” rating and a $7.00 price objective on the stock. Cowen reiterated a “hold” rating on shares of Sunesis Pharmaceuticals in a research report on Thursday, November 2nd. Zacks Investment Research cut shares of Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. Cantor Fitzgerald reiterated a “hold” rating and set a $3.00 target price on shares of Sunesis Pharmaceuticals in a research report on Wednesday, September 27th. Finally, Wells Fargo & Co cut shares of Sunesis Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $2.70 to $2.00 in a research report on Tuesday, December 5th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $3.75.
Shares of Sunesis Pharmaceuticals (SNSS) opened at $4.25 on Friday. The company has a market cap of $145.56, a price-to-earnings ratio of -2.43 and a beta of 1.53. Sunesis Pharmaceuticals has a 1 year low of $1.82 and a 1 year high of $4.45. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of -0.34.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.06). During the same quarter in the prior year, the company posted ($0.62) EPS. equities research analysts forecast that Sunesis Pharmaceuticals will post -1.58 earnings per share for the current fiscal year.
In other news, major shareholder Mpm Oncology Impact Management acquired 25,300 shares of the stock in a transaction that occurred on Thursday, November 2nd. The stock was acquired at an average price of $2.59 per share, for a total transaction of $65,527.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Dayton Misfeldt acquired 400,000 shares of the stock in a transaction that occurred on Friday, October 27th. The stock was purchased at an average price of $2.00 per share, with a total value of $800,000.00. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 506,800 shares of company stock valued at $1,091,282. 10.21% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Sunesis Pharmaceuticals (SNSS) Share Price” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/01/14/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-sunesis-pharmaceuticals-snss-stock-price.html.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.